Scholarlink

<p>This study aimed to characterize the distribution of uropathogens in positive urine cultures, their antimicrobial resistance patterns, and epidemiological features from 2019 to 2024, providing evidence for rational empirical antimicrobial therapy. We retrospectively analyzed clinical urine specimens for pathogen identification using the VITEK MS system and conducted antimicrobial susceptibility testing with the VITEK-2 system and Kirby-Bauer method. Among 1,978 positive specimens, 70.3% were bacterial and 29.7% were fungal. The predominant bacterial pathogens were <i>E. coli</i> (35.1%) and <i>K. pneumoniae</i> (24.2%), while fungal isolates were dominated by <i>C. albicans</i> (64.9%). We also observed a notable increase in the intrinsically fluconazole-resistant <i>C. krusei</i> over the study period. <i>E. coli</i> showed low resistance to nitrofurantoin, amikacin, and piperacillin/tazobactam, but high resistance to ampicillin and fluoroquinolones. Over the six years, carbapenem resistance in <i>E. coli</i> declined steadily, while resistance in <i>K. pneumoniae</i> fluctuated, peaking at 59.4% in 2020, highlighting the need for ongoing surveillance. Our findings indicate that fluoroquinolones and ampicillin should be avoided as first-line agents, while nitrofurantoin, amikacin, and piperacillin/tazobactam are viable options for treating <i>E. coli</i>-associated positive urine cultures. Furthermore, the high and fluctuating carbapenem resistance in <i>K. pneumoniae</i> underscores the need for strengthened antimicrobial stewardship, including enhanced surveillance and tailored prescribing, to optimize empirical therapy, curb resistance, and improve clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Distribution and antimicrobial resistance of uropathogens: a 6-year retrospective single-center study (2019–2024)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Weiyi Wu,
  • Qiong Wu,
  • Lizhong Han,
  • Lianxiang Xing,
  • Zhiwu Dong

摘要

This study aimed to characterize the distribution of uropathogens in positive urine cultures, their antimicrobial resistance patterns, and epidemiological features from 2019 to 2024, providing evidence for rational empirical antimicrobial therapy. We retrospectively analyzed clinical urine specimens for pathogen identification using the VITEK MS system and conducted antimicrobial susceptibility testing with the VITEK-2 system and Kirby-Bauer method. Among 1,978 positive specimens, 70.3% were bacterial and 29.7% were fungal. The predominant bacterial pathogens were E. coli (35.1%) and K. pneumoniae (24.2%), while fungal isolates were dominated by C. albicans (64.9%). We also observed a notable increase in the intrinsically fluconazole-resistant C. krusei over the study period. E. coli showed low resistance to nitrofurantoin, amikacin, and piperacillin/tazobactam, but high resistance to ampicillin and fluoroquinolones. Over the six years, carbapenem resistance in E. coli declined steadily, while resistance in K. pneumoniae fluctuated, peaking at 59.4% in 2020, highlighting the need for ongoing surveillance. Our findings indicate that fluoroquinolones and ampicillin should be avoided as first-line agents, while nitrofurantoin, amikacin, and piperacillin/tazobactam are viable options for treating E. coli-associated positive urine cultures. Furthermore, the high and fluctuating carbapenem resistance in K. pneumoniae underscores the need for strengthened antimicrobial stewardship, including enhanced surveillance and tailored prescribing, to optimize empirical therapy, curb resistance, and improve clinical outcomes.